ArticleScientific reports2025
Expression and prognostic value of EGF-like domain multiple 6 in uterine corpus endometrial carcinoma and its correlation with immune cell infiltration.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification of neutrophil extracellular traps-related genes as feature genes and potential therapeutic targets in pulmonary hypertension.Journal of thoracic disease · 2026Article
- Prognostic significance of ZNF695 in uterine corpus endometrial carcinoma: single-cell and immune infiltration analyses.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Uterine corpus endometrial carcinoma (UCEC) is a common malignancy that affects the female reproductive tract, and it is characterized by high rates of both morbidity and mortality. This study investigated epidermal growth factor-like domain multiple 6 (EGFL6) as a potential diagnostic and prognostic biomarker in patients with UCEC. RNA sequencing data and clinical information from patients with UCEC were obtained from The Cancer Genome Atlas. Logistic regression analysis was used to assess the correlations between EGFL6 expression and clinical features. Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and Gene Set Enrichment Analysis were performed to evaluate the EGFL6-related biological characteristics and signaling pathways. Immunohistochemistry was performed using UCEC tissue microarrays to assess EGFL6 expression. The Kaplan-Meier method and Cox regression analyses were used to evaluate the prognostic significance of EGFL6. Three nomograms were developed to predict overall survival, disease-specific survival, and progression-free interval probabilities at 1, 3, and 5 years after diagnosis. The expression of EGFL6 was validated using quantitative real-time PCR. Our findings demonstrate that EGFL6 is markedly overexpressed in UCEC and is associated with unfavorable clinical characteristics, including clinical stage and histological type. Gene Ontology, Kyoto Encyclopedia of Genes and Genome and Gene Set Enrichment Analysis highlighted its possible association with various key signaling pathways. Additionally, EGFL6 expression was associated with decreased immune cell infiltration, particularly regulatory T cells (Tregs) (r = - 0.219, p < 0.001) and CD8 + T cells (r = - 0.217, p < 0.001). Overall, EGFL6 expression was associated with a poor patient prognosis in patients. In conclusion, EGFL6 is a potential biomarker for UCEC, and could greatly improve of diagnostic and prognostic evaluation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.